Catalyst Dossier · compiled by CeliA 🧫
UCB (UCBJY)
Healthcare · market cap $53.9B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
UCB (UCBJY) is a Belgian biopharmaceutical company with ~8,600 employees and a market cap of approximately $53.9B, focused on neurology and immunology. Its commercial portfolio includes established assets such as Bimekizumab (IL-17A/F inhibitor, psoriasis/PsA), Zilucoplan and Rozanolixizumab (both in generalized myasthenia gravis), Brivaracetam and Lacosamide (epilepsy), and Certolizumab Pegol (multiple inflammatory indications). The near-term catalyst calendar is dense, with multiple Phase 3 readouts expected through Q1 2027, anchored by Bimekizumab label expansions and gMG data.
The catalyst path
- 2026-09-30 (est.)Phase 3 · Staccato alprazolamimp 9/10
- 2026-11-16 (est.)Phase 3 · Zilucoplanimp 9/10
- 2026-12-21 (est.)Phase 3 · Bimekizumabimp 9/10
- 2027-02-25 (est.)Phase 3 · Brivaracetamimp 9/10
- 2027-03-09 (est.)Phase 3 · Bimekizumabimp 9/10
- 2027-03-19 (est.)Phase 3 · Bimekizumabimp 9/10
- 2027-05-06 (est.)Phase 3 · Rozanolixizumabimp 9/10
- 2027-05-17 (est.)Phase 2 · Galvokimigimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Antiepileptic drugs with market authorization available per country | Phase 3 | Epilepsy |
| SPM 927 | Phase 3 | Partial Seizures With or Without Secondary Generalization |
| Cimzia | Phase 3 | Crohn Disease |
| Etanercept | Phase 3 | Psoriasis |
| Certolizumab Pegol | Phase 3 | Rheumatoid Arthritis |
| Brivaracetam | Phase 3 | Epilepsy |
| Secukinumab | Phase 3 | Chronic Plaque Psoriasis |
| levocetirizine dihydrochloride | Phase 3 | Rhinitis |
| Ketotifen | Phase 3 | Rhinitis, Allergic, Perennial |
| Lacosamide | Phase 3 | Epilepsy |
| Bimekizumab | Phase 3 | Chronic Plaque Psoriasis |
| Rotigotine Nasal Spray | Phase 2 | Restless Legs Syndrome |
| UCB0022 | Phase 2 | Parkinson Disease |
| Certolizumab Pegol + Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis |
| Kemstro | Phase 3 | Multiple Sclerosis |
| Rozanolixizumab | Phase 3 | Generalized Myasthenia Gravis |
| UCB7665 | Phase 2 | Thrombocytopenia |
| Levocetirizine | Phase 3 | Rhinitis, Allergic, Seasonal |
| SPM927/Lacosamide | Phase 2 | Painful Diabetic Neuropathy |
| Rotigotine | Phase 3 | Restless Legs Syndrome |
Price & technical context
3-month
-16.5%
6-month
-18.5%
12-month
-0.4%
52-wk range
$115.23–$168.19
vs 50-day MA
-7.2%
vs 200-day MA
-16.1%
Realized vol
38.6%
Max drawdown
-30.4%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for UCBJY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.